Myocardial blood flow enhancer

The term 'myocardial blood flow enhancer' refers to a functional and pharmacological classification of agents rather than a specific molecular target such as a single receptor or enzyme [StatPearls: Vasodilators]. These agents are designed to increase the delivery of oxygenated blood to the heart muscle by promoting the relaxation of coronary vascular smooth muscle and decreasing coronary resistance. This broad category encompasses several distinct drug classes, including organic nitrates, adenosine receptor agonists, and calcium channel blockers, each of which acts on different molecular pathways like the nitric oxide-cGMP axis or purinergic signaling [NCBI: Regulation of Coronary Blood Flow]. Clinically, these enhancers are essential for managing symptoms of stable and unstable angina, treating coronary artery disease, and serving as pharmacological stress agents in diagnostic myocardial perfusion imaging [Mayo Clinic: Angina]. Because the term describes a physiological effect rather than a discrete biological entity, it is considered a clinical designation of drug action. Therapeutic use requires careful monitoring for systemic side effects such as hypotension or the 'coronary steal' phenomenon, where blood flow is diverted away from the most ischemic areas of the myocardium [AHA: Cardiac Medications].

Other names

Coronary vasodilatorMyocardial perfusion enhancerAnti-anginal agentVasodilator

Myocardial blood flow enhancers operate through multiple molecular pathways to reduce coronary vascular resistance. Primary mechanisms include the stimulation of the nitric oxide-soluble guanylate cyclase-cGMP pathway (e.g., nitrates), the activation of adenosine A2A receptors to increase intracellular cAMP (e.g., regadenoson), or the inhibition of L-type calcium channels to prevent vascular smooth muscle contraction (e.g., calcium channel blockers), all leading to vasodilation [StatPearls: Vasodilators; NCBI: Regulation of Coronary Blood Flow].